COVID-19 guidance: research and development

Policy 44: European Medicines Agency policy on the handling of competing interests of scientific committees’ members and experts

Procedures for monograph and list entry establishment

Herbal medicinal product: Pelargonii radix, Pelargonii radix, F: Assessment finalised

Human medicines European public assessment report (EPAR): Zimbus Breezhaler, indacaterol,glycopyrronium,mometasone furoate, Asthma, Date of authorisation: 03/07/2020, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Atectura Breezhaler, indacaterol,mometasone, Asthma, Date of authorisation: 30/05/2020, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): RoActemra, tocilizumab, Arthritis, Rheumatoid;Arthritis, Juvenile Rheumatoid;Cytokine Release Syndrome;Giant Cell Arteritis;COVID-19 virus infection, Date of authorisation: 15/01/2009, Revision: 41, Status: Authorised

Human medicines European public assessment report (EPAR): Yervoy, ipilimumab, Melanoma;Carcinoma, Renal Cell;Carcinoma, Non-Small-Cell Lung;Mesothelioma, Malignant;Colorectal Neoplasms, Date of authorisation: 13/07/2011, Revision: 53, Status: Authorised

Human medicines European public assessment report (EPAR): Enerzair Breezhaler, indacaterol,glycopyrronium bromide,mometasone, Asthma, Date of authorisation: 03/07/2020, Revision: 6, Status: Authorised

Opinions and letters of support on the qualification of novel methodologies for medicine development